Skip to main content

Advertisement

SpringerLink
Log in

Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Supplementation therapy with plain vitamin D plus calcium is in general regarded as effective prevention or first-step treatment of glucocorticoid-induced osteoporosis (GIOP). The aim of our study was to compare the therapeutic efficacy of the D-hormone analog alfacalcidol with plain vitamin D in patients with established GIOP with or without vertebral fractures. Patients on long-term glucocorticoid (GC) therapy were included as matched pairs to receive randomly either 1 μg alfacalcidol plus 500 mg calcium per day (group A, n=103) or 1,000 IU vitamin D3 plus 500 mg calcium (group B, n=101). The two groups were well matched in terms of mean age, sex ratio, mean height and weight, daily dosage, and duration of GC therapy, and the percentages of the three underlying diseases included chronic obstructive pulmonary disease, rheumatoid arthritis, and polymyalgia rheumatica. The baseline mean bone mineral density (BMD) values at the lumbar spine for the two groups were −3.26 (alfacalcidol) and −3.25 (vitamin D3) and, at the femoral neck, −2.81 and −2.84, respectively (T scores). Rates of prevalent vertebral and nonvertebral fractures did not differ between groups. During the 3-year study, we observed a median percentage increase of BMD at the lumbar spine of 2.4% in group A and a loss of 0.8% in group B (P<0.0001). There also was a larger median increase at the femoral neck in group A (1.2%) than in group B (0.8%) (P<0.006). The 3-year rates of patients with at least one new vertebral fracture were 9.7% among those assigned to the alfacalcidol group and 24.8% in the vitamin D group (risk reduction 0.61, 95% CI 0.24–0.81, P=0.005). The 3-year rates of patients with at least one new nonvertebral fracture were 15% in the alfacalcidol group and 25% in the vitamin D group (risk reduction 0.41, 95% CI 0.06–0.68, P=0.081). The 3-year rates of patients with at least one new fracture of any kind were 19.4% among those treated with alfacalcidol and 40.65% with vitamin D (risk reduction 0.52, 95% CI 0.25–0.71, P=0.001). In accordance with the observed fracture rates, the alfacalcidol group showed a substantially larger decrease in back pain than the plain vitamin D group (P<0.0001). Generally, side effects in both groups were mild, and only three patients in the alfacalcidol group and two in the vitamin D group had moderate hypercalcemia. We conclude that alfacalcidol plus calcium is highly superior to plain vitamin D3 plus calcium in the treatment of established GIOP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.

Similar content being viewed by others

Notes

  1. Alpha D3 produced by TEVA. Brand names in Germany: Bondiol, Doss

References

  1. Schacht E (1999) Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int 65:317–327

    Article  CAS  PubMed  Google Scholar 

  2. Cantorna MT, Hayes CE, DeLuca HF (1998) 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 128:68–72

    CAS  PubMed  Google Scholar 

  3. DeLuca HF, Cantorna MT (2001) Vitamin D: its role and uses in immunology. FASEB J 15:2579–2585

    Article  CAS  PubMed  Google Scholar 

  4. Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D, Pavlica L, Stefanovic D (1999) Disease modifying and immunomodulatory effects of high dose 1α(OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 17:453–456

    CAS  PubMed  Google Scholar 

  5. Hein G, Oelzner P (2000) Vitamin D-Metabolite bei rheumatoider Arthritis: Befunde–Hypothesen–Konsequenzen. Z Rheumatol 59 [Suppl 1]:I/28–I/32

  6. Scharla SH, Schacht E, Bawey S, Kamilli I, Holle D, Lempert UG (2003) Pleiotropic effects of 1α-hydroxyvitamin D (alfacalcidol) in patients with rheumatoid arthritis. Bone [submitted]

  7. Van Cleemput J, Daenen W, Geusens P, Dequeker J, van de Werf F, Vanhaecke J (1996) Prevention of bone loss in cardiac transplant recipients. Transplantation 61:1495–1499

    PubMed  Google Scholar 

  8. Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkès CJ, Nielsen K (1999) Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 9:75–81

    Article  CAS  PubMed  Google Scholar 

  9. Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J, Speer G, Bossanyi A (2000) Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 59 [Suppl 1]:I 48–52

  10. Sambrook PN, Birmingham J, Kelly PJ, Kempler S, Pocock NA, Eisman JA (1993) Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol and calcitonin. N Engl J Med 328:1747–1752

    Article  CAS  PubMed  Google Scholar 

  11. Sambrook PN, Henderson NK, Keogh A, Macdonald P, Glanville A, Spratt P, Bergin P, Ebeling P, Eisman J (2000) Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 15:1818–1824

    CAS  PubMed  Google Scholar 

  12. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, Tugwell P, Gordon M, Steele M, Webber C, Goldsmith CH (1996) Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3 year follow up. J Rheumatol 23:995–1000

    CAS  PubMed  Google Scholar 

  13. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1996) Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 125:961–968

    CAS  PubMed  Google Scholar 

  14. Lau WK-H, Baylink DJ (2001) Treatment of 1,25(OH)2D3 (D-hormone) deficiency/resistance with D-hormone and analogs. Osteologie 10:28–39

    Google Scholar 

  15. Shane E, Addesso V, Namerow P, Maybaum S, Staron R, Lo S, Zucker M, Pardi S, Mancini D (2002) Prevention of bone loss after cardiac transplantation with alendronate or calcitriol: efficacy and safety. J Bone Miner Res 17:S135

    Google Scholar 

  16. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 44:1496–1503

    Article  PubMed  Google Scholar 

  17. Richy F, Reginster JY (2002) Efficacy of D-hormones in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int [Suppl 3]:S21

  18. Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T, Ogawa N (1994) Effects of 1α-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54:370–376

    CAS  PubMed  Google Scholar 

  19. Hayashi Y, Fujita T, Inoue T (1992) Decrease of vertebral fracture in osteoporotics by administration of 1α-hydroxy-vitamin D3. J Bone Miner Metab 10:50–54

    Google Scholar 

  20. Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357–362

    Google Scholar 

  21. Gallagher JC, Fowler SE, Detter JR, Sherman SS (2001) Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 86:3618–3628

    Google Scholar 

  22. Boland R (1986) Role of vitamin D in skeletal muscle function. Endocr Rev 7:434–448

    CAS  PubMed  Google Scholar 

  23. Ebert-Dümig R, Jovanovic M, Köhrle J, Jakob F (2001) Human 25(OH) vitamin D3-1α-hydroxylase promoter is regulated by TNFα-in HepG2 and HEK-293 cell lines. Exp Clin Endocrinol Diabetes 109 [Suppl 1]:S26

  24. Oelzner P, Muller A, Deschner F, Huller M, Abendroth K, Hein G, Stein G (1998) Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 62:193–198

    Article  CAS  PubMed  Google Scholar 

  25. Haug CJ, Aukrust P, Haug E, Morkrid L, Muller F, Froland SS (1998) Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 83:3832–3838

    CAS  PubMed  Google Scholar 

  26. Lempert UG, Minne HW, Albrecht B, Scharla SH, Matthes F, Ziegler R (1989) 1,25-dihydroxy-vitamin D3 prevents the decrease of bone mineral appositional rate in rats with inflammation-mediated osteopenia (IMO). Bone Miner 7:149–158

    CAS  PubMed  Google Scholar 

  27. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E (1999) The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int 65:311–316

    Article  CAS  PubMed  Google Scholar 

  28. Saag KG for the Glucocorticoid-Induced Osteoporosis Intervention Study Group (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292–299

    Article  CAS  PubMed  Google Scholar 

  29. Cohen S, Levy RM, Keller M, Boling E, Emkey R, Greenwald M, Zizic T, Wallach S, Sewell K, Lukert B, Achselrod D, Chines A (1999) Risedronate therapy prevents corticosteroid-induced bone loss—a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318

    Article  CAS  PubMed  Google Scholar 

  30. Sarkar S, Mitlak BH, Wong M, Stock IL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifen therapy. J Bone Miner Res 17:1–10

    CAS  PubMed  Google Scholar 

  31. Ito M, Azuma Y, Takagi H, Komoriya K, Ohta T, Kawaguchi H (2002) Curative effect of combined treatment with alendronate and 1α-hydroxyvitamin D3 on bone loss by ovariectomy in aged rats. Jpn J Pharmacol 89:255–266

    Article  CAS  PubMed  Google Scholar 

  32. Erben RG, Mosekilde L, Thomsen JS, Weber K, Stahr K, Leyshon A, Smith SY, Phipps R (2002) Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1α,25-dihydroxyvitamin D3. J Bone Miner Res 17:1498–1511

    CAS  PubMed  Google Scholar 

  33. Wei LJ, Lachin JM (1984) Two-sample asymptotically distribution-free tests for incomplete multivariate observations. J Am Stat Assoc 79:653–661

    Google Scholar 

  34. Thall PF, Lachin JM (1988) Analysis of recurrent events: nonparametric methods for random interval count data. J Am Stat Assoc 83:339–347

    Google Scholar 

  35. Lachin JM (1992) Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Stat Med 11:1151–1170

    CAS  PubMed  Google Scholar 

  36. Colditz, GA, Miller JN, Mosteller F (1988) Measuring gain in the evaluation of medical technology: the probability of a better outcome. J Technol Assessment Health Care 4:637–642

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Clinic 4, Leverkusen Clinic, Dhünnberg 60, 51375, Leverkusen, Germany

    J. D. Ringe, A. Dorst & H. Faber

  2. Metabolic Bone Disease Unit, Balgrist University Clinic, Zurich, Switzerland

    E. Schacht

  3. idv Datenanalyse und Versuchsplanung, Gauting, Germany

    V. W. Rahlfs

Authors
  1. J. D. Ringe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Dorst
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Faber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Schacht
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. W. Rahlfs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. D. Ringe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ringe, J.D., Dorst, A., Faber, H. et al. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 24, 63–70 (2004). https://doi.org/10.1007/s00296-003-0361-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-003-0361-9

Keywords

Search

Navigation